CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
AV-1 100 mg +3 moredrug
Likely dose
AV-1 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06799741
NCT06799741Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3

AbViro LLC·interventional·Posted Jan 29, 2025·Updated Mar 31, 2026

In Brief

A Phase 2 clinical trial evaluating AV-1 100 mg, AV-1 300 mg, and 2 other interventions for DENV-3 Controlled Human Infection Model. Completed, enrolled 85 participants across 3 sites.

Detailed Summary

The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDENV-3 Controlled Human Infection Model
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedJan 29, 2025
Enrollment StartJan 7, 2025
Primary CompletionMar 11, 2026
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 1.4 years ago

Interventions

AV-1 100 mgdrug

human monoclonal antibody (mAb) intravenous solution or

AV-1 300 mgdrug

human monoclonal antibody (mAb) intravenous solution or

AV-1 900 mgdrug

human monoclonal antibody (mAb) intravenous solution or

Placebodrug

(0.9% saline intravenous solution) 12:2